SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova - Quaterly Results

02 Aug 2022 Evaluate
The revenue zoomed 14.52% to Rs. 2045.70 millions for the quarter ended June 2022 as compared to Rs. 1786.40 millions during the corresponding quarter last year.The Net Loss for the quarter ended June 2022 is Rs. -51.80 millions as compared to Net Loss of Rs. -7.60 millions of corresponding quarter ended June 2021A decline of 58.70 millions was observed in the OP in the quarter ended June 2022 from 108.40 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 2045.70 1786.40 14.52 2045.70 1786.40 14.52 877.50 27095.00 -96.76
Other Income 102.40 42.80 139.25 102.40 42.80 139.25 1258.70 478.80 162.89
PBIDT 58.70 108.40 -45.85 58.70 108.40 -45.85 1190.90 4749.40 -74.93
Interest 31.50 26.70 17.98 31.50 26.70 17.98 305.90 1018.00 -69.95
PBDT 27.20 81.70 -66.71 27.20 81.70 -66.71 885.00 3731.40 -76.28
Depreciation 92.10 91.60 0.55 92.10 91.60 0.55 62.50 999.70 -93.75
PBT -64.90 -9.90 555.56 -64.90 -9.90 555.56 822.50 2731.70 -69.89
TAX -13.10 -2.30 469.57 -13.10 -2.30 469.57 37.50 586.90 -93.61
Deferred Tax -13.10 -3.20 309.38 -13.10 -3.20 309.38 -99.10 132.50 -174.79
PAT -51.80 -7.60 581.58 -51.80 -7.60 581.58 785.00 2144.80 -63.40
Equity 159.30 159.30 0.00 159.30 159.30 0.00 159.30 159.30 0.00
PBIDTM(%) 2.87 6.07 -52.71 2.87 6.07 -52.71 135.72 17.53 674.25

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×